Context
The number of reported cases with SARS-CoV-2 vaccine-induced subacute thyroiditis (SAT) and Graves' disease (GD) is growing. However, active debate continues about managing such side effects and the safety of repeat or booster doses of the vaccines in such cases.
Objectives
This study aims to present long-term clinical follow-up of SARS-CoV-2 vaccine-induced SAT or GD cases and provide data regarding the safety of re-vaccinations.
Methods
Patients diagnosed with SARS-CoV-2 vaccine-induced SAT or GD were included. Data regarding the long-term clinical follow-up of SARS-CoV-2 vaccine-induced SAT, and GD cases and outcomes of repeat or booster SARS-CoV-2 vaccinations were documented. The literature, including cases of SARS-CoV-2 vaccine-induced SAT or GD, was reviewed.
Results
Fifteen patients with SARS-CoV-2 vaccine-induced SAT and four with GD were included. Pfizer/BioNTech COVID-19 vaccine (BNT162b2) was associated with symptoms in a majority of cases with SAT and all with GD. Median time from vaccination to symptom onset was seven and 11.5 days, while seven and two patients required medical treatment in SAT and GD groups, respectively. Remission was documented in ten SAT patients, with a median time to remission of 11.5 weeks. No exacerbation/recurrence of SAT occurred in seven of nine patients who received a repeat vaccination dose, while symptoms of SAT worsened following the second vaccination in two cases. None of the patients has experienced severe side effects that could be associated with re-vaccinations.
Conclusions
Re-vaccinations appear to be safe in patients with SARS-CoV-2 vaccine-induced SAT cases, while more evidence is needed regarding SARS-CoV-2 vaccine-induced GD.
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in reproductive-aged women, characterized by hyperandrogenism, oligo/anovulation, and polycystic ovarian morphology. Combined oral contraceptives (COCs), along with lifestyle modifications, represent the first-line medical treatment for the long-term management of PCOS. Containing low doses of estrogen and different types of progestin, COCs restore menstrual cyclicity, improve hyperandrogenism, and provide additional benefits such as reducing the risk of endometrial cancer. However, potential cardiometabolic risk associated with these agents has been a concern. COCs increase the risk of venous thromboembolism (VTE), related both to the dose of estrogen and the type of progestin involved. Arterial thrombotic events related to COC use occur much less frequently, and usually not a concern for young patients. All patients diagnosed with PCOS should be carefully evaluated for cardiometabolic risk factors at baseline, before initiating a COC. Age, smoking, obesity, glucose intolerance or diabetes, hypertension, dyslipidemia, thrombophilia, and family history of VTE should be recorded. Patients should be re-assessed at consecutive visits, more closely if any baseline cardiometabolic risk factor is present. Individual risk assessment is the key in order to avoid unfavorable outcomes related to COC use in women with PCOS.
Primary hypophysitis (PH) is a rare autoimmune inflammatory disease of the
pituitary gland. The aim of the study was to evaluate clinical
characteristics, disease management, and outcomes of cases with PH. Medical
records of PH patients admitted to Hacettepe University Hospital between
1999 and 2017 were analyzed retrospectively. Paraffin-embedded pathology
blocks were obtained for both re-examination and IgG4 immunostaining. Twenty
PH patients (15 females, 5 males) were evaluated. Mean age at diagnosis was
41.5±13.4 years. Some form of hormonal disorder was present in
63.2% of cases, hypogonadism (66.6%) being the most common.
Panhypopituitarism was present in 36.8%. All patients had pituitary
gland enlargement on magnetic resonance imaging; stalk thickening and loss
of neurohypophyseal bright spot were present in 17.6 and 23.5%,
respectively. Lymphocytic hypophysitis was the most common histopathological
subtype (50%). Among pathology specimens available for IgG and IgG4
immunostaining (n=10), none fulfilled the criteria for IgG4-related
hypophysitis. Four patients were given glucocorticoid treatment in diverse
protocols; as initial therapy in 3. Sixteen cases underwent surgery, 7 of
whom due to neuro-ophthalmologic involvement. Only 1 patient was observed
without any intervention. Reduction of pituitary enlargement was seen in all
surgical and glucocorticoid treated cases. None of the surgical patients
showed hormonal improvement while one case in glucocorticoid group improved.
PH should be considered in the differential diagnosis of sellar masses
causing hormonal deficiencies. MRI findings are usually helpful, but not yet
sufficient for definitive diagnosis of PH. Treatment usually improves
symptoms and reduces sellar masses while hormonal recovery is less
common.
Coronavirus Disease 2019 (COVID-19) is characterized with a wide range of clinical presentations from asymptomatic to severe disease. In patients with severe disease, the main causes of mortality have been acute respiratory distress syndrome, cytokine storm and thrombotic events. Although all factors that may be associated with disease severity are not yet clear, older age remains a leading risk factor. While age-related immune changes may be at the bottom of severe course of COVID-19, age-related hormonal changes have considerable importance due to their interactions with these immune alterations, and also with endothelial dysfunction and comorbid cardiometabolic disorders. This review aims to provide the current scientific evidence on the pathogenetic mechanisms underlying the pathway to severe COVID-19, from a collaborative perspective of age-related immune and hormonal changes together, in accordance with the clinical knowledge acquired thus far.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.